Wanbury P/E Ratio
Wanbury (WANBURY) P/E ratio is 19.55 (Moderate), EPS (TTM) ₹9.32, current price ₹263.28 on NSE vs historical average P/E of 8.17 (100.0th percentile) — Moderate - Fairly valued. For live price, revenue and the complete fundamental profile, see WANBURY company profile.
Current Valuation Metrics
Valuation Signal
Sector Context
Earnings Breakdown (TTM)
WANBURY P/E Ratio — Valuation Signal & Historical Context
Wanbury P/E 19.55 vs historical average 8.17, range 6.78–9.56 — signal: Fairly Valued. Analyse WANBURY ownership pattern to track promoter, FII and institutional holdings.
- Current PE is 139.3% above historical average
- Trading at discount to sector average PE of 49.16
Wanbury P/E Ratio Historical Trend
WANBURY annual price-to-earnings ratio — 2 years, EPS and year-end price. Current P/E 19.55 vs historical average 8.17. View Wanbury yearly highs lows for the annual high/low range and current price position.
WANBURY Historical P/E Ratio — EPS, Year-End Price & Valuation
Wanbury annual P/E ratio, EPS (₹), year-end price and valuation category on NSE.
| Year | P/E Ratio | EPS (₹) | Year-end Price (₹) | Exchange | Valuation |
|---|---|---|---|---|---|
| 2024 | 9.56 | 13.42 | ₹128.30 | NSE | Low |
| 2023 | 6.78 | 7.13 | ₹48.35 | NSE | Low |
WANBURY vs Healthcare Peers — P/E Ratio Comparison
Wanbury P/E 19.55 vs Healthcare average 49.16, median 27.18 — range 1.17–869.57.
| Company | Symbol | P/E Ratio | Market Cap (₹ Cr) | Valuation |
|---|---|---|---|---|
| Welcure Drugs & Pharmace… | WELCURE | 1.17 | ₹43 | Low |
| Murae Organisor | MURAE | 2.86 | ₹41 | Low |
| Ind Swift Laboratories | INDSWFTLAB | 4.93 | ₹1,136 | Low |
| Amwill Health Care | AMWILL | 5.67 | ₹64 | Low |
| Medicamen Organics | MEDIORG | 6.4 | ₹27 | Low |
| Zenith Drugs | ZENITHDRUG | 6.83 | ₹69 | Low |
| Unichem Laboratories | UNICHEMLAB | 7.99 | ₹2,364 | Low |
| Galaxy Medicare | GML | 8.78 | ₹31 | Low |
| Brooks Laboratories | BROOKS | 9.86 | ₹211 | Low |
| Accretion Pharmaceuticals | ACCPL | 10.92 | ₹78 | Low |